Immunic Inc (IMUX) Stock Price, Quote & News

Company Profile

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restor...

Industry: Biotechnology

Sector: Healthcare

Phone: 332 255 9818

Website: imux.com

Address:

1200 Avenue of the Americas, Suite 200, New York, United States

ErnieWorthing84 Nov. 14 at 9:18 PM

$IMUX While none of us should bet on or hope for a BO here, it's not inconceivable ...

3 · Reply

Jw242 Nov. 14 at 9:01 PM

$IMUX enjoy the weekend longs. Pain train

0 · Reply

Mattjen Nov. 14 at 7:13 PM

$IMUX The stop-loss traders really got shaken out yesterday. Weak hands are mostly gone, and the accumulation over the last few sessions has been massive. To me, this looks like quiet positioning ahead of bigger news — though it could also just be typical biotech volatility. Either way, I'm holding tight with my 26,700 shares.

0 · Reply

DrewskiC99 Nov. 14 at 6:15 PM

$IMUX have a small position here. Think this could be an undervalued gem but also see huge downside

0 · Reply

Jw242 Nov. 14 at 6:10 PM

$IMUX Dunzo

1 · Reply

Johnnyb1973 Nov. 14 at 6:09 PM

$IMUX Here comes pride in the back stretch!

1 · Reply

Mvvh1987 Nov. 14 at 6:04 PM

$IMUX If Merck is willing to spend $9.2B on an antiviral prevention asset, imagine the value of a potential first-in-class Nurr1 activator with signals in RRMS + PPMS a multi-billion MS space where Roche and Novartis desperately need the next blockbuster.

2 · Reply

Jw242 Nov. 14 at 5:29 PM

$IMUX here comes the pain I’m sure

0 · Reply

Mattjen Nov. 14 at 2:03 PM

$IMUX When the overall market is red, especially biotech or small-cap sectors, stocks like IMUX often move with the tide, not because of anything company-specific. Here’s what today’s market conditions usually mean for a name like IMUX: Market-wide selling pulls down higher-beta stocks Small-cap biotechs tend to drop more on red days because they’re considered higher risk. So a 4–8% move down on a rough market day isn’t unusual even with no bad news. The S&P and DOW were also trending down.... it's okay.

1 · Reply

JarvisFlow Nov. 14 at 1:02 PM

HC Wainwright & Co. has updated their rating for Immunic ( $IMUX ) to Buy with a price target of 8.

1 · Reply

Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 29, 2025, 6:30 AM EDT - 16 days ago

Immunic to Participate in Industry and Investor Conferences in November

Oct 1, 2025, 6:30 AM EDT - 6 weeks ago

Immunic to Participate in Scientific and Investor Conferences in October

Sep 25, 2025, 6:30 AM EDT - 7 weeks ago

Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis

Sep 9, 2025, 6:30 AM EDT - 2 months ago

Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis

Sep 4, 2025, 6:30 AM EDT - 2 months ago

Immunic to Participate in Investor and Scientific Conferences in September

Aug 7, 2025, 6:30 AM EDT - 3 months ago

Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jun 24, 2025, 6:30 AM EDT - 5 months ago

Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis

Jun 9, 2025, 5:51 PM EDT - 5 months ago

Immunic Post-Readout: Reiterating Strong Buy As Big Drop Appears Unwarranted

Jun 5, 2025, 6:30 AM EDT - 5 months ago

Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS

Jun 3, 2025, 4:01 PM EDT - 5 months ago

Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering

Jun 2, 2025, 6:30 AM EDT - 5 months ago

Immunic to Participate in Investor, Scientific and Industry Conferences in June

May 29, 2025, 7:05 AM EDT - 6 months ago

Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering

May 28, 2025, 4:02 PM EDT - 6 months ago

Immunic, Inc. Announces Proposed Public Offering

May 2, 2025, 6:30 AM EDT - 7 months ago

Immunic to Participate in Scientific and Industry Conferences in May

Apr 30, 2025, 7:30 AM EDT - 7 months ago

Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial

Apr 28, 2025, 2:09 AM EDT - 7 months ago

Immunic: A Strong Buy With Imminent Data Readout That Should Send Shares Higher

Apr 10, 2025, 1:00 PM EDT - 7 months ago

Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

Apr 9, 2025, 8:10 AM EDT - 7 months ago

Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

Apr 1, 2025, 6:30 AM EDT - 8 months ago

Immunic, Inc. to Participate in Scientific and Industry Conferences in April

Mar 3, 2025, 6:30 AM EST - 9 months ago

Immunic to Participate in Scientific and Investor Conferences in March

Feb 26, 2025, 6:30 AM EST - 9 months ago

Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis

Feb 20, 2025, 7:30 AM EST - 9 months ago

Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing

Feb 4, 2025, 6:30 AM EST - 10 months ago

Immunic to Participate in Investor and Scientific Conferences in February

Jan 7, 2025, 6:30 AM EST - 11 months ago

Immunic Highlights 2024 Accomplishments and Upcoming Milestones

Nov 26, 2024, 6:30 AM EST - 1 year ago

Immunic, Inc. to Participate in Investor Conference in December

Nov 13, 2024, 6:30 AM EST - 1 year ago

Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology

Nov 9, 2024, 8:37 AM EST - 1 year ago

Immunic, Inc. (IMUX) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 6:30 AM EST - 1 year ago

Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 31, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update

Oct 29, 2024, 6:30 AM EDT - 1 year ago

Immunic to Participate in Industry, Scientific and Investor Conferences in November

Oct 22, 2024, 6:30 AM EDT - 1 year ago

Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis

Sep 18, 2024, 6:30 AM EDT - 1 year ago

Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis

Sep 4, 2024, 6:30 AM EDT - 1 year ago

Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome

Aug 28, 2024, 6:30 AM EDT - 1 year ago

Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September

Aug 9, 2024, 6:55 PM EDT - 1 year ago

Immunic, Inc. (IMUX) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 1, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update

Jul 24, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec

Jul 9, 2024, 6:30 AM EDT - 1 year ago

Immunic Appoints Jason Tardio as Chief Operating Officer and President

May 28, 2024, 6:30 AM EDT - 1 year ago

Immunic to Participate in Industry and Scientific Conferences in June

May 8, 2024, 2:20 PM EDT - 1 year ago

Immunic, Inc. (IMUX) Q1 2024 Earnings Call Transcript

May 8, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 6, 2024, 6:30 AM EDT - 1 year ago

Immunic to Participate in Investor and Scientific Conferences in May

May 1, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update

Apr 30, 2024, 6:30 AM EDT - 1 year ago

Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation

Apr 4, 2024, 6:30 AM EDT - 1 year ago

Immunic to Host MS R&D Day and Participate in Investor Conferences in April

Mar 20, 2024, 6:30 AM EDT - 1 year ago

Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States

Mar 7, 2024, 6:30 AM EST - 1 year ago

Immunic to Participate in Investor and Scientific Conferences in March

Feb 29, 2024, 6:30 AM EST - 1 year ago

Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024

ErnieWorthing84 Nov. 14 at 9:18 PM

$IMUX While none of us should bet on or hope for a BO here, it's not inconceivable ...

3 · Reply

Jw242 Nov. 14 at 9:01 PM

$IMUX enjoy the weekend longs. Pain train

0 · Reply

Mattjen Nov. 14 at 7:13 PM

0 · Reply

DrewskiC99 Nov. 14 at 6:15 PM

$IMUX have a small position here. Think this could be an undervalued gem but also see huge downside

0 · Reply

Jw242 Nov. 14 at 6:10 PM

$IMUX Dunzo

1 · Reply

Johnnyb1973 Nov. 14 at 6:09 PM

$IMUX Here comes pride in the back stretch!

1 · Reply

Mvvh1987 Nov. 14 at 6:04 PM

2 · Reply

Jw242 Nov. 14 at 5:29 PM

$IMUX here comes the pain I’m sure

0 · Reply

Mattjen Nov. 14 at 2:03 PM

1 · Reply

JarvisFlow Nov. 14 at 1:02 PM

HC Wainwright & Co. has updated their rating for Immunic ( $IMUX ) to Buy with a price target of 8.

1 · Reply

rizmanasjr Nov. 14 at 12:24 PM

$IMUX

0 · Reply

Tradergrows Nov. 14 at 3:23 AM

$IMUX Silence is golden. Don’t assume nothing is happening behind the scenes. https://www.proactiveinvestors.com/companies/news/1082464/immunic-ceo-on-q3-highlights-ectrims-2025-and-upcoming-milestones-1082464.html

1 · Reply

TREBLALBERT Nov. 13 at 9:35 PM

$IMUX An offering in these conditions is not possible! RS immediately and then an offering. Otherwise they will have to come out with very good news and then big offering. IMO

1 · Reply

Johnnyb1973 Nov. 13 at 7:03 PM

$IMUX Its getting rough out here

0 · Reply

SennaFan Nov. 13 at 5:55 PM

$IMUX very likely the will do offerings. They don't have cash to last them another year.

0 · Reply

Mattjen Nov. 13 at 5:20 PM

$IMUX $IMUX – Quietly Building Momentum 🚀 I know IMUX (Immunic Inc.) has been through a rough stretch, but things are starting to look really interesting. The company has one of the cleanest MS (multiple sclerosis) profiles in development — and their oral therapy could compete directly with existing drugs like Ocrevus, without the infusions or heavy side effects. Volume has been trending up, sentiment is improving, and analysts like Jason Kolbert still have double-digit price targets ($10+). After the recent earnings call, management reiterated strong cash runway into 2026 and hinted at ongoing partnership discussions. With BIO-Europe behind us and more conferences ahead, the setup feels right for news before year-end. Sometimes the quiet periods are when the most strategic moves happen. I’m holding my shares and watching closely — IMUX may finally be ready to turn the corner. 💪 #IMUX #biotech #MS #stocks #undervalued #longterm

1 · Reply

AitorMenta Nov. 13 at 3:50 PM

$IMUX i think next fucking news a massive dilution!!!! They are doing the worst management possible

0 · Reply

Doom_Gloom_AR Nov. 13 at 3:29 PM

$IMUX Cash situation is very bad, I do hope these guys make it to the p3 readouts without massive dilution.

1 · Reply

Jw242 Nov. 13 at 3:06 PM

$IMUX yep. Low volume pain. Market just doesn’t trust our management without a massive wad of cash.

0 · Reply

anachartanalyst Nov. 13 at 2:02 PM

$IMUX https://anachart.com/wp-content/uploads/ana_temp/1763042505_soc-img.jpg

4 · Reply

JarvisFlow Nov. 13 at 1:47 PM

D. Boral Capital updates rating for Immunic ( $IMUX ) to Buy, target set at 10 → 8.

0 · Reply

takingstock73 Nov. 13 at 1:42 PM

$IMUX any thoughts on when earnings , today,? delayed ?

1 · Reply

Market Cap	70.29M
Revenue (ttm)	0.00
Net Income (ttm)	-100.51M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,263,400
Avg Vol	1,431,576
Day's Range	N/A - N/A
Shares Out	98.65M
Stochastic %K	90%
Beta	1.53
Analysts	Strong Sell
Price Target	$5.98